On Tuesday, Trevi Therapeutics Inc (NASDAQ: TRVI) opened higher 4.20% from the last session, before settling in for the closing price of $5.47. Price fluctuations for TRVI have ranged from $2.36 to $7.48 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 27.09% over the last five years. Company’s average yearly earnings per share was noted 8.52% at the time writing. With a float of $69.87 million, this company’s outstanding shares have now reached $99.89 million.
The firm has a total of 26 workers. Let’s measure their productivity. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Trevi Therapeutics Inc (TRVI) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Trevi Therapeutics Inc is 41.36%, while institutional ownership is 43.98%. The most recent insider transaction that took place on Mar 25 ’25, was worth 17,365. In this transaction Chief Scientific Officer of this company sold 2,631 shares at a rate of $6.60, taking the stock ownership to the 221,373 shares. Before that another transaction happened on Mar 21 ’25, when Company’s President & CEO sold 5,263 for $6.58, making the entire transaction worth $34,625. This insider now owns 213,313 shares in total.
Trevi Therapeutics Inc (TRVI) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 8.52% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -12.29% during the next five years compared to 27.09% growth over the previous five years of trading.
Trevi Therapeutics Inc (NASDAQ: TRVI) Trading Performance Indicators
Check out the current performance indicators for Trevi Therapeutics Inc (TRVI). In the past quarter, the stock posted a quick ratio of 15.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.45, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.54 in one year’s time.
Technical Analysis of Trevi Therapeutics Inc (TRVI)
Analysing the last 5-days average volume posted by the [Trevi Therapeutics Inc, TRVI], we can find that recorded value of 1.56 million was lower than the volume posted last year of 1.86 million. As of the previous 9 days, the stock’s Stochastic %D was 17.54%.
During the past 100 days, Trevi Therapeutics Inc’s (TRVI) raw stochastic average was set at 52.01%, which indicates a significant increase from 24.79% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 37.56% in the past 14 days, which was lower than the 78.75% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.30, while its 200-day Moving Average is $4.63. Now, the first resistance to watch is $5.86. This is followed by the second major resistance level at $6.02. The third major resistance level sits at $6.21. If the price goes on to break the first support level at $5.51, it is likely to go to the next support level at $5.31. Should the price break the second support level, the third support level stands at $5.15.
Trevi Therapeutics Inc (NASDAQ: TRVI) Key Stats
There are currently 117,293K shares outstanding in the company with a market cap of 679.12 million. Presently, the company’s annual sales total 0 K according to its annual income of -47,910 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -10,340 K.
